Skip to content

Clinical Study of the Valeo OL Interbody Fusion Device for Posterior Lumbar Interbody fusion versus PEEK: the Silicon Nitride and PEEK (SNAP) trial.

Clinical Study of the Valeo OL Interbody Fusion Device for Posterior Lumbar Interbody fusion versus PEEK: the Silicon Nitride and PEEK (SNAP) trial. - Silicon Nitride and PEEK (SNAP) trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36245
Enrollment
100
Registered
2011-11-01
Start date
2012-02-23
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar degenerative disc disease/ spinal stenosis

Interventions

All patients will be planned for spine surgery in which the Valeo or the PEEk cage is used. Patient will be followed for 2-years (3 months, 6 months, 12 months and 24 months) for CT scans and to com

Sponsors

Amedica Corporation
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: _Subjects must be 18-75 years old. _ at least 6 months of back pain/leg pain _Grade 3 or higher disc degeneration on the MRI (by the Pfirrmann classification) with or without nerve root compression

Exclusion criteria

Exclusion criteria: •Osteoporosis •Patients with prior failed fusion at the same level •Degenerative scoliosis •Degenerative spondylolisthesis greater than Grade II •Pregnancy •Psychiatric or mental disease •Alcoholism (drinking more than 5 units per day) •Active infection or prior infection at the surgical site •Active cancer •Insufficient language skills to complete questionnaires •Participation in another study •More than two symptomatic levels that need fusion

Design outcomes

Primary

MeasureTime frame
Primary Endpoint Disability as measured with the MRDQ.

Secondary

MeasureTime frame
Secondary Endpoint Fusion rate will be evaluated by comparing flexion and extension radiographs correlated to clinical improvements on the MRQD/SF-36 and VAS. Fusion quality will be verified with a CT scan at 12 months

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)